Nebulized treprostinil (Tyvaso) reduced lung function decline from idiopathic pulmonary fibrosis (IPF) in the pivotal TETON-1 ...
Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.
About 40% of at-risk patients with COPD did not receive maintenance therapy despite having frequent or severe exacerbations.
Ralinepag, a prostacyclin receptor agonist, added to background therapy decreased the risk for a clinical worsening event in ...
Patients with severe asthma who are typically underrepresented in clinical studies experienced improved outcomes with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results